Morgan Stanley
APRE icon

Morgan Stanley’s Aprea Therapeutics APRE Stock Holding History

Morgan Stanley’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Sell
22,330
-54,700
-71% -$43K ﹤0.01% 6787
2025
Q4 		$65.7K Buy
77,030
+11,222
+17% +$13.8K ﹤0.01% 6352
2025
Q3 		$97.1K Buy
65,808
+2,477
+4% +$4.08K ﹤0.01% 6166
2025
Q2 		$107K Buy
63,331
+30,523
+93% +$52K ﹤0.01% 6102
2025
Q1 		$66.9K Sell
32,808
-4,000
-11% -$12.5K ﹤0.01% 6176
2024
Q4 		$121K Buy
36,808
+2,600
+8% +$8.69K ﹤0.01% 5979
2024
Q3 		$94.1K Buy
34,208
+4,390
+15% +$15.5K ﹤0.01% 6033
2024
Q2 		$121K Buy
29,818
+3,000
+11% +$15.5K ﹤0.01% 5893
2024
Q1 		$179K Sell
26,818
-7,618
-22% -$47.3K ﹤0.01% 5771
2023
Q4 		$162K Buy
34,436
+19,874
+136% +$81.4K ﹤0.01% 6025
2023
Q3 		$60.7K Sell
14,562
-722
-5% -$2.63K ﹤0.01% 6083
2023
Q2 		$48.1K Buy
15,284
+733
+5% +$2.73K ﹤0.01% 6227
2023
Q1 		$64.6K Buy
14,551
+758
+5% +$5.6K ﹤0.01% 6191
2022
Q4 		$91.3K Sell
13,793
-1,808
-12% -$19.1K ﹤0.01% 6015
2022
Q3 		$202K Sell
15,601
-1,991
-11% -$35.3K ﹤0.01% 5723
2022
Q2 		$264K Buy
17,592
+5,245
+42% +$121K ﹤0.01% 5754
2022
Q1 		$459K Sell
12,347
-3,964
-24% -$162K ﹤0.01% 5456
2021
Q4 		$936K Buy
16,311
+7,063
+76% +$624K ﹤0.01% 5119
2021
Q3 		$945K Sell
9,248
-41,741
-82% -$3.79M ﹤0.01% 5081
2021
Q2 		$4.97M Buy
50,989
+1,083
+2% +$100K ﹤0.01% 3781
2021
Q1 		$5.09M Buy
49,906
+26,255
+111% +$3.06M ﹤0.01% 3393
2020
Q4 		$2.33M Buy
23,651
+20,262
+598% +$9.63M ﹤0.01% 4025
2020
Q3 		$1.63M Sell
3,389
-144
-4% -$80.6K ﹤0.01% 3836
2020
Q2 		$2.74M Buy
3,533
+3,508
+14,032% +$2.3M ﹤0.01% 3286
2020
Q1 		$17K Sell
25
-645
-96% -$473K ﹤0.01% 5860
2019
Q4 		$615K Buy
+670
New +$369K ﹤0.01% 4813

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley's APRE Position: Q1 2026 in Review

Morgan Stanley reduced its Aprea Therapeutics (APRE) stake by 71% in Q1 2026, selling an estimated $43K and leaving 22,330 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #6787.

Morgan Stanley first reported a position in APRE in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.09M in Q1 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Morgan Stanley held 22,330 shares of Aprea Therapeutics worth $17K as of Q1 2026.
  • Morgan Stanley sold 54,700 Aprea Therapeutics shares in Q1 2026, an estimated $43K.
  • Aprea Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6787 holding.
  • Morgan Stanley first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Morgan Stanley's Aprea Therapeutics position peaked at $5.09M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.